Shares of Talon Therapeutics Inc. (OTC: TLON), a biopharmaceutical company engaged in the development and commercialization of cancer therapies, rose sharply in trading today.
TLON shares ended the day 2.04% higher at $1 on above average volume of 2.30 million.
TLON shares gained today after the company announced on Thursday that its Marqibo® received accelerated approval from the FDA for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti leukemia therapies.
Commenting on the development, Steven R. Deitcher, MD, President and CEO of Talon Therapeutics, said that TLON is delighted that Marqibo will be available to a patient population with an underserved hematologic malignancy and this represents a transformational event for Talon and fulfillment of the company’s most important goal.
Shares of Fuse Science Inc. (PINK: DROP), an innovative consumer products company, rose sharply in trading today.
DROP shares ended the day 7.18% higher at $0.118 on above average volume of 3.72 million. The stock touched an intra-day high of $0.12.
Earlier this week, DROP announced that it entered into a licensing letter of intent (LOI) with Macular Health LLC, which is one of the leading manufacturers of macular degeneration nutritional supplements.
The licensing agreement, which is DROP’s first in the health and nutrition field, accelerates the application of DROP’s unique delivery technology into a new industry category. Final terms of the licensing agreement are required to be in place and executed within 30 days.
As part of the license agreement, DROP will offer limited license of its proprietary delivery technology to Macular Health. Meanwhile, Macular Health will look to expand its existing line of supplements therapy by delivering formulations for patients with macular degeneration that may deliver benefits faster and more effectively by using Fuse Science’s technology.
Macular Health’s CEO Jeffery McAnnally said that DROP and their expert team of scientists will help the company advance the treatment for millions of people afflicted with the leading cause of blindness in the U.S.
Brian Tuffin, CEO of Fuse Science, said that DROP is extremely excited to combine its proprietary technology with Macular Health to deliver solutions for patients suffering from macular degeneration.
Recent Comments